Company Filing History:
Years Active: 2011
Title: The Innovations of Jörg Volkland: Pioneering Anti-IL2 Antibodies
Introduction
Jörg Volkland, a notable inventor from Neuried, Germany, has made significant contributions to the field of biotechnology. With one patent to his name, his work focuses on the development of innovative therapeutic antibodies that target human interleukin-2 (IL2). This invention has potential implications for treating various autoimmune diseases and cancers.
Latest Patents
Volkland's patent, titled "Anti-IL2 Antibodies," relates to a humanized monoclonal antibody or a fragment designed to specifically bind to human IL2. The invention is particularly remarkable as it neutralizes the activity of human IL2 by binding prior to, during, and after its interaction with the human IL2-receptor. A unique feature of his antibody is the light chain variable region, which contains the contiguous amino acid sequence KAPKA at positions 42-46 in its second framework region.
Career Highlights
Jörg Volkland currently works at Micromet AG, a company known for its innovative approaches in the field of biopharmaceuticals. His research and invention contribute significantly to the company's mission to develop targeted therapies for cancer and other serious diseases. His focus on monoclonal antibodies exemplifies the advancements being made in medical treatment options.
Collaborations
Throughout his career, Volkland has collaborated with esteemed colleagues, including Patrick Bäuerle and John Lumsden. These partnerships enhance the research environment and foster the exchange of ideas that drive innovation in their field. Working alongside other experts allows for a multidisciplinary approach in tackling complex biological challenges.
Conclusion
Jörg Volkland's work on anti-IL2 antibodies marks an important milestone in the field of immunology and biotherapy. His contributions through his patent highlight the potential for targeted treatments to revolutionize how we approach various diseases. As the landscape of biomedical research continues to evolve, the innovations stemming from his work are sure to leave a lasting impact on the industry.